1307821

APR 2 1 2008

□ other (please specify):

□ Estimated

FORM D	OMB APPROVAL		
SEC UNITED STATES Mail Processing SECURITIES AND EXCHANGE COMMISSION Section Washington, D.C. 20549	OMB NUMBER: 3235-0076 Expires: April 30, 2008 Estimated average burden hours per response		
FORM D NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION	SEC USE ONLY Prefix Serial DATE RECEIVED		
Name of Offering (□ check if this is an amendment and name has changed, and indicate change.) 6% Convertible Promissory Notes and Warrants			
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ So Type of Filing: ■ New Filing □ Amendment	ection 4(6) □ ULOE		
A. BASIC IDENTIFICATION	DATA		
1. Enter the information requested about the issuer Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	08046997		
Gloucester Pharmaceuticals, Inc.			
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)		
One Broadway, 14th floor, Cambridge, MA 02142	617-583-1300		
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices)	Telephone Number (Including Area Code)		
Brief Description of Business:	_		
Cancer therapeutics development company	PROCESSE		
Type of Business Organization			

GENERAL INSTRUCTIONS

Actual or Estimated Date of Incorporation or Organization

Federal:

corporation

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

Actual

☐ limited partnership, already formed limited partnership, to be formed Month Year 07

02

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

2. Enter the information requested for the following:						
 Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; 						
 Each executive officer and direct 	ector of corporat	e issuers and of corporate	general and managing pa	irtners of partners	ship issuers; and	
Each general and managing pa	rtner of partners	<u> </u>				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Mohr, Joseph S.						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
c/o Gloucester Pharmaceuticals, Inc., O	na Braadway 1	M th floor Cambridge N	1A 02142			
Check Box(es) that Apply:	□ Promoter	Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)	Tromoter	B Bonenera owner	D DAGGATTO GITTON			
Vogelbaum, Martin Business or Residence Address	(Number and	Street, City, State, Zip Co	ide)			
Business of Residence Address	(14dinoci and .	oneci, City, Biate, Zip Co	ac)			
c/o Gloucester Pharmaceuticals, Inc., O						
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Schnell, David						
Business or Residence Address	(Number and S	itreet, City, State, Zip Coo	de)			
c/o Gloucester Pharmaceuticals, Inc., C	na Proadway	14th Acor Combridge N	1A 02142			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)		B Delicitoral Owner				
,						
Moorin, Jay Business or Residence Address	(Number and S	Street, City, State, Zip Coo	da)			
Business of Residence Address	(Number and a	street, City, State, Zip Co	ue)			
c/o Gloucester Pharmaceuticals, Inc., C	ne Broadway,	14 th floor, Cambridge, N	1A 02142			
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Harrison, Seth						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
c/o Gloucester Pharmaceuticals, Inc., C	Ann Decodures:	14 th floor Combridge N	4.4. 021.42			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)		- Delicheral Owner	D sacount officer	<u> </u>		
•						
Prospect Venture Partners II, L.P. Business or Residence Address	(Number and	Street, City, State, Zip Co	vde)			
Business of Residence Address	(Number and	Bireet, City, State, 21p Co	,de)			
435 Tasso Street, Suite 200, Palo Alto,	CA 94301					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
ProQuest Investments III, L.P.				_		
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)			
600 Alexander Park, Suite 204, Princet	on N.I 08540					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
,						
CIBC WMC Inc. Business or Residence Address	(Number and	Street, City, State, Zip C	ode)			
Business of Residence Address	נוזעוווטכו מוע	onice, ony, state, alp o	outy			
425 Lexington Avenue, 9th floor, New Y	ork, NY 10017					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Rho Capital Partners						
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)			

Carnegie Hall Tower, 152 West 57th Street, 23rd floor, New York, NY 10019

A. BASIC IDENTIFICATION DATA

		A. BASIC IDENT	IFICATION DATA		
 Each executive officer and c Each general and managing 	, if the issuer has be ng the power to vot director of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10	% or more of a c artners of partner	lass of equity securities of the issuer; ship issuers; and
Check Box(es) that Apply:	C) Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua	al)				
Verdine, Gregory Ph.D.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Gloucester Pharmaceuticals, Inc.,	One Broadway	14 th floor Cambridge N	1A 02142		
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua		- Delicitorial G willow			
,	,				
Apple Tree Partners II, L.P. Business or Residence Address	(Number and	Street, City, State, Zip Co	da)		
Business of Residence Address	(Pulliper and	Street, City, State, Zip Co	ac)		
501 Kings Highway East, Suite E-1, I		5			
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua	al)				
Hayden, Donald J.					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	de)		
c/o Głoucester Pharmaceuticals, Inc.,	O B J	140 g Combuidae N	14 02142		
Check Box(es) that Apply:	One Broadway, D	□ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua		D Belleficial Owner	Executive Officer	<u> </u>	O Central and of Managing Farmer
	,				
Nichols, Jean			1.3		
Business or Residence Address	(Number and	Street, City, State, Zip Co	ide)		
c/o Gloucester Pharmaceuticals, Inc.,	One Broadway,	14th floor, Cambridge, M	IA 02142		
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua	al)				
Vrolijk, Nicholas					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ide)		
c/o Gloucester Pharmaceuticals, Inc. Check Box(es) that Apply:				- Di	D.C I d/a-Managina Partaus
Full Name (Last name first, if individual	□ Promoter	☐ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name mist, if mulvidua	ai)				
Colowick, Alan		···			
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Gloucester Pharmaceuticals, Inc.	One Broadway.	14 th floor, Cambridge, M	1A 02142		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individua					
Business or Residence Address	(Number and	Street, City, State, Zip Co	nde)		2222.
Daylings of Nesidence Address	(Humber and	onco, ony, biane, zip o	, , , , , , , , , , , , , , , , , , ,		

.

•

B. INFORMATION ABOUT OFFERING							
	Yes	No					
1.		•					
2.	\$n/a						
-	What is the minimum investment that will be accepted from any individual?	Yes	No				
3.	Does the offering permit joint ownership of a single unit?	•	D				
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.						
Full Non-	Name (Last name first, if individual)						
	ness or Residence Address (Number and Street, City, State, Zip Code)						
17401	ness of residence (talifies and street, only, state, say society)						
Nam	ne of Associated Broker or Dealer						
<u> </u>	124 D Lived Har Callabert and Callab Development						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	All States					
	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				
Full	name (Last name first, if individual)	· · · · · · · · · · · · · · · · · · ·					
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	ne of Associated Broker or Dealer						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	(Check "All States" or check individual States)	All States					
[] [] []	AL] _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ (ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				
Full	Name (Last name first, if individual)						
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)						
Name of Associated Broker or Dealer							
States in which Person Listed Has Solicited or Intends to Solicit Purchasers							
	(All States					
_ [/ _ [/ _ [/	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ (MO] _ [PA] _ [PR]				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\pi\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	s
	Equity	\$	s
	D Common D Preferred		
	Convertible Securities (including warrants)	\$ 3,000,000	\$ <u>1,993,719</u>
	Partnership Interests	\$	\$
	Other (Specify)	s	S
	Total	\$ 3,000,000	\$ <u>1,993,719</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	7	\$ <u>1,993,719</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		9
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering Rule 505	Type of Security	Dollar Amount Sold
	Regulation A		s
	Rule 504		\$
	Total		
			\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	0	s
	Printing and Engraving Costs	0	s
	Legal Fees	•	\$_20,000
	Accounting Fees	٥	s
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	0	s
	Other Expenses (identify)	٥	s
	Total		\$_20,000

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS b. Enter the difference between the aggregate offering price given in response to Part C - Question I and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." \$___2,980,000 Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Officers, Directors, Payments To & Affiliates Others Salaries and fees Purchase of real estate.... a Purchase, rental or leasing and installation of machinery and equipment \Box Construction or leasing of plant buildings and facilities Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) Repayment of indebtedness..... Working capital..... \$ 2,980,000 П Other (specify): 0 \$ 2,980,000 Column Totals..... Total Payments Listed (column totals added) **■ \$__ 2,980,000** D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Signature Date April **/O**, 2008

Issuer (Print or Type) Gloucester Pharmaceuticals, Inc. Title of Signer (Print or Type) Name of Signer (Print or Type) Chief Executive Officer Alan Colowick

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

